Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)

The NCI PDXNet Consortium

Research output: Contribution to journalComment/debatepeer-review

Abstract

In this Article the Competing interests statement inadvertently omitted a statement for M.T.L. and L.E.D. The competing financial interests for M.T.L. should have read: ‘M.T.L. is a founder and limited partner in StemMed Ltd. and a manager in StemMed Holdings, its general partner. He is a founder and equity stakeholder in Tvardi Theraeutics Inc. Some PDXs are exclusively licensed to StemMed Ltd. resulting in royalty income to M.T.L.’. The competing financial interests for L.E.D. should have read, ‘L.E.D. is a compensated employee of StemMed Ltd’. The PDF and HTML versions of the Article have been corrected.

Original languageEnglish (US)
Article number294
JournalNature communications
Volume13
Issue number1
DOIs
StatePublished - Dec 2022

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Fingerprint

Dive into the research topics of 'Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)'. Together they form a unique fingerprint.

Cite this